# | Title | Journal | Year | Citations |
---|
1 | Functions of DNA methylation: islands, start sites, gene bodies and beyond | Nature Reviews Genetics | 2012 | 4,840 |
2 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Lancet, The | 2017 | 3,224 |
3 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study | Lancet Oncology, The | 2017 | 2,058 |
4 | Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 | Autophagy | 2021 | 1,430 |
5 | Cancer Genetics and Epigenetics: Two Sides of the Same Coin? | Cancer Cell | 2012 | 966 |
6 | Can we safely target the WNT pathway? | Nature Reviews Drug Discovery | 2014 | 840 |
7 | Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials | Annals of Oncology | 2017 | 654 |
8 | HER kinase inhibition in patients with HER2- and HER3-mutant cancers | Nature | 2018 | 572 |
9 | Genome architectures revealed by tethered chromosome conformation capture and population-based modeling | Nature Biotechnology | 2012 | 524 |
10 | DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation | Molecular Cancer Therapeutics | 2009 | 518 |
11 | Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting | Biochemical Journal | 2011 | 445 |
12 | Discovery of common and rare genetic risk variants for colorectal cancer | Nature Genetics | 2019 | 377 |
13 | Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers | Oncotarget | 2014 | 367 |
14 | Environmental epigenetics: prospects for studying epigenetic mediation of exposure–response relationships | Human Genetics | 2012 | 294 |
15 | ctDNA guiding adjuvant immunotherapy in urothelial carcinoma | Nature | 2021 | 293 |
16 | First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study | Journal of Clinical Oncology | 2022 | 283 |
17 | Circular RNA profile in gliomas revealed by identification tool UROBORUS | Nucleic Acids Research | 2016 | 269 |
18 | Cell Surface Relocalization of the Endoplasmic Reticulum Chaperone and Unfolded Protein Response Regulator GRP78/BiP | Journal of Biological Chemistry | 2010 | 268 |
19 | The critical role of GRP78 in physiologic and pathologic stress | Current Opinion in Cell Biology | 2011 | 260 |
20 | DNA methylation loss in late-replicating domains is linked to mitotic cell division | Nature Genetics | 2018 | 258 |
21 | Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma | Journal of Hepatology | 2020 | 254 |
22 | Role of the unfolded protein response, GRP78 and GRP94 in organ homeostasis | Journal of Cellular Physiology | 2015 | 242 |
23 | Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome | Journal of Clinical Oncology | 2019 | 234 |
24 | Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors | Gastroenterology | 2018 | 226 |
25 | Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial | Lancet Oncology, The | 2021 | 225 |
26 | Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes | European Journal of Cancer | 2017 | 212 |
27 | motifbreakR: an R/Bioconductor package for predicting variant effects at transcription factor binding sites | Bioinformatics | 2015 | 208 |
28 | Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study | The Lancet Gastroenterology and Hepatology | 2021 | 205 |
29 | FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer | European Journal of Cancer | 2015 | 202 |
30 | Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial | Lancet Oncology, The | 2016 | 200 |
31 | Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis | Nature Communications | 2020 | 193 |
32 | CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). | Journal of Clinical Oncology | 2014 | 178 |
33 | Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. | Journal of Clinical Oncology | 2019 | 178 |
34 | Genetic and environmental effects on body mass index from infancy to the onset of adulthood: an individual-based pooled analysis of 45 twin cohorts participating in the COllaborative project of Development of Anthropometrical measures in Twins (CODATwins) study | American Journal of Clinical Nutrition | 2016 | 175 |
35 | Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence | Clinical Cancer Research | 2012 | 173 |
36 | Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma | Journal of Hepatology | 2020 | 165 |
37 | Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma | JAMA Oncology | 2015 | 164 |
38 | Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis | Clinical Cancer Research | 2013 | 154 |
39 | Safely targeting cancer stem cells via selective catenin coactivator antagonism | Cancer Science | 2014 | 152 |
40 | Unique DNA Methylation Patterns Distinguish Noninvasive and Invasive Urothelial Cancers and Establish an Epigenetic Field Defect in Premalignant Tissue | Cancer Research | 2010 | 148 |
41 | Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial | Lancet Oncology, The | 2017 | 148 |
42 | Association of Polygenic Risk Scores for Multiple Cancers in a Phenome-wide Study: Results from The Michigan Genomics Initiative | American Journal of Human Genetics | 2018 | 147 |
43 | Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study | Blood | 2020 | 144 |
44 | Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented Melanomas | JAMA Dermatology | 2014 | 142 |
45 | Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis | Gastroenterology | 2012 | 140 |
46 | Characterization and Mechanism of Stress-induced Translocation of 78-Kilodalton Glucose-regulated Protein (GRP78) to the Cell Surface | Journal of Biological Chemistry | 2015 | 139 |
47 | Genome-wide association study of colorectal cancer identifies six new susceptibility loci | Nature Communications | 2015 | 138 |
48 | Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial | Annals of Oncology | 2019 | 136 |
49 | XRCC4:DNA ligase IV can ligate incompatible DNA ends and can ligate across gaps | EMBO Journal | 2007 | 135 |
50 | Novel Common Genetic Susceptibility Loci for Colorectal Cancer | Journal of the National Cancer Institute | 2019 | 129 |